Why have so few proteomic biomarkers “survived” validation? (Sample size and independent validation considerations)

The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?

(2012) Eleftherios P Diamandis   BMC Medicine

Comparison of Random Forest and Pipeline Pilot Naïve Bayes in Prospective QSAR Predictions

(2012) Bin Chen et al.   Journal of Chemical Information and Modeling

Biomarker Tests Need Closer Scrutiny, IOM Concludes

(2012) J. Kaiser   SCIENCE

Identification of serum biomarkers of hepatocarcinoma through liquid chromatography/mass spectrometry-based metabonomic method

(2011) Feng Chen et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY

Measuring and visualizing the stability of biomarker selection techniques

(2011) Ludwig Lausser et al.   COMPUTATIONAL STATISTICS

Biomarker research in prostate cancer—towards utility, not futility

(2011) Sheng Fei Oon et al.   Nature Reviews Urology

A Comparison of Methods for Classifying Clinical Samples Based on Proteomics Data: A Case Study for Statistical and Machine Learning Approaches

(2011) Dayle L. Sampson et al.   PLoS One

Over-optimism in bioinformatics: an illustration

(2010) M. Jelizarow et al.   BIOINFORMATICS

On the Development of Plasma Protein Biomarkers

(2010) Silvia Surinova et al.   JOURNAL OF PROTEOME RESEARCH

Pattern-based diagnosis and screening of differentially expressed serum proteins for rheumatoid arthritis by proteomic fingerprinting

(2010) Li Long et al.   RHEUMATOLOGY INTERNATIONAL

Bioinformatics for protein biomarker panel classification: what is needed to bring biomarker panels intoin vitrodiagnostics?

(2009) Xavier Robin et al.   Expert Review of Proteomics

Conditional Variable Importance for Random Forests

(2008) Carolin Strobl et al.   BMC BIOINFORMATICS